A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)

20260 citationsJournal Articlehybrid Open Access

Authors

Berzosertib (200 mg/m<sup>2</sup> iv weekly) was safe when combined with chemoradiation but did not improve complete response rate in LA-HNSCC.

Published in: Cancer

Volume 132, Issue 6, pp. e70346-e70346

Field-Weighted Citation Impact: 0.00